News

Revenue amounted to 138.8 MSEK (127.9), an increase of 8.5 percent, of which a negative organic growth of 1.9 percent. The quarter was negatively impacted by the phase-out of non-strategic products in surgical instruments that began in early 2025 and a negative currency effect. Adjusted for these two factors, underlying organic growth would have amounted to 7.3 percent. “We had a continued strong...

Stille AB (publ) announces new Executive Management team, with the appointment of Niklas Tyrén as Group CFO and Martin Richardson as Group COO. Stille AB today announces a new Executive Management and group structure to support the company’s continued international growth. The new organization strengthens group capabilities in Finance, Operations and QA/RA. We are announcing the appointment...

Stille AB (publ) informs that Johan Lundholm has decided to leave his position as Business Unit Manager for Surgical Tables of Stille to pursue a new opportunity outside the company. "I would like to thank Johan for his contributions over the past four years and wish him all the best in his future endeavors. He has played an important role in driving the commercial development of the surgical...

Stille AB (publ) (“Stille”) today confirms that the previously announced acquisition of Surgical Holdings Ltd (“Surgical Holdings”) has been completed. All closing conditions have been satisfied, and the shares have now been transferred to Stille. As previously communicated, the total consideration of c. GBP 7.7 million (corresponding to c. SEK 99.4 million) on a cash and debt-free...

Stille AB (publ) today presents the report for the second quarter 2025. Revenue amounted to 124.7 MSEK (142.6). Order intake remained strong but was impacted by continued supply-chain constraints, the phase-out of non-strategic products, and currency headwinds. “Order intake remained strong and largely in line with our growth targets, providing a solid foundation for recovery,” says Ulrik...

Stille AB (publ) (“Stille”) has entered into an agreement to acquire all shares outstanding in Surgical Holdings (“Surgical Holdings”) for a consideration of approximately GBP 7.7 million (corresponding to SEK 100 million) on a cash and debt-free basis. Through the acquisition, Stille continues its strategic expansion, further strengthening its geographic reach, product- and...

Torshälla, Sweden – 9 May 2025 – The Board of Directors of Stille AB (“Stille”), a leading provider of premium surgical instruments and advanced surgical tables for high-precision procedures, is pleased to announce the appointment of Ulrik Berthelsen as its new Chief Executive Officer, effective 12 May 2025. With a distinguished background in the medical technology sector...

The 2025 annual general meeting in Stille AB was held on Wednesday, May 7, 2025, on Norrlandsgatan 11 in Stockholm. The main resolutions passed at the annual general meeting were as follows. More detailed information about the contents of the resolutions may be obtained from the complete notice of the annual general meeting and the complete proposals, which are available on the company’s website...

Stille AB (publ) informs that Niklas Carlén has decided to step down from his position as Chief Financial Officer (CFO) of Stille to pursue a new opportunity outside the company. "I would like to thank Niklas for his significant contributions over the past five years and wish him all the best in his future endeavors. He has played an important role in many key initiatives at Stille, including...

Stille AB (publ) today presents the report for the first quarter 2025. Revenue amounted to 129.3 MSEK (139.7) impacted by temporary delivery restrictions and the phase-out of non-strategic products.“Stille starts 2025 with a quarter marked by temporary challenges.” says Torbjörn Sköld but also points out,“Order intakeremained strong, in line with financial targets, providing...